![]() KEYNOTE-355 (, NCT02819518) compared pembro + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated locally recurrent inoperable or metastatic TNBC. ![]() IOB Institute of Oncology, Quiron Group & Vall d´Hebron Institute of Oncology (VHIO), Madrid & Barcelona, Spain, Princess Margaret Cancer Centre, Toronto, ON, Canada, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland, Seoul National University Hospital, Seoul, South Korea, Pantai Hospital, Kuala Lumpur, Malaysia, Arturo Lopez Perez Foundation, Santiago, Chile, Republican Clinical Oncology Dispensary of the Ministry of Public Health of Bashkortostan Republic, Ufa, Russian Federation, Centro de Hematologia e Oncologia, Porto Alegre, Brazil, Aichi Cancer Center Hospital, Nagoya, Japan, National Hospital Organization, Osaka National Hospital, Osaka, Japan, Oncomedica S.A., Monteria, Colombia, Ege University Medical Faculty, Izmir, Turkey, Peter MacCallum Cancer Institute, Melbourne, VIC, Australia, Merck & Co., Inc., Kenilworth, NJ, Barts Cancer Institute, Centre for Experimental Cancer Medicine, London, United Kingdom Abstract Disclosuresīackground: Pembrolizumab (pembro) monotherapy showed promising antitumor activity and manageable safety in patients (pts) with metastatic TNBC in KEYNOTE-012, -086 and -119.
0 Comments
Leave a Reply. |